Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 3/2017

01-03-2017 | Original Article

Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival

Authors: Marcin Mardas, Marta Stelmach-Mardas, Radosław Madry

Published in: Supportive Care in Cancer | Issue 3/2017

Login to get access

Abstract

Purpose

The aim of this study was to evaluate whether body weight changes in patients undergoing chemotherapy for epithelial ovarian cancer (EOC) influence progression-free survival (PFS) and overall survival (OS).

Methods

An analysis of 190 patients diagnosed with ovarian cancer after first-line chemotherapy was conducted. Changes in body weight were assessed by comparing measurements at baseline to those of the third and sixth cycles of chemotherapy. PFS and OS were calculated with the Kaplan–Meier method and multivariate Cox model.

Results

Significant reduction in body weight in advanced EOC was observed with no changes in early EOC. Significant differences in PFS were observed in advanced EOC patients that lost more than 5 % of their body weight (6 months), maintained weight (13 months), or gained more than 5 % of their body weight (15 months). Similarly, significant differences in OS were noted in advanced EOC at the following time points: 24.3, 42.4, and 66.2 months. No effect was reported for early EOC patients. The multivariate Cox analysis showed significant body weight changes from the first to the sixth chemotherapy cycle for PFS (HR = 0.97; 95 % CI 0.95–0.99) and OS (HR = 0.94; 95 % CI 0.91–0.97) as well as from the first to the third chemotherapy cycle for OS (HR = 0.93; 95 % CI 0.88–0.98).

Conclusions

Body weight changes can be recognized as a prognostic factor for PFS and OS in advanced EOC patients undergoing chemotherapy. Weight loss is associated with poorer survival while weight gain improved outcomes.
Appendix
Available only for authorised users
Literature
1.
Reynolds EA, Moller KA (2006) A review and an update on the screening of epithelial ovarian cancer. Curr Probl Cancer 30:203–232CrossRefPubMed
2.
Kearney N, Miller M, Maguire R, Dolan S, MacDonald R, McLeod J, Maher L, Sinclair L, Norrie J, Wengström Y (2008) WISECARE+: results of a European study of a nursing intervention for the management of chemotherapy-related symptoms. Eur J Oncol Nurs 12(5):443–448CrossRefPubMed
3.
Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G, Kaye S (2013) Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 108(2):250–258CrossRefPubMedPubMedCentral
4.
Bandera EV, Kushi LH, Rodriguez-Rodriguez L (2009) Nutritional factors in ovarian cancer survival. Nutr Cancer 61:580–586CrossRefPubMed
5.
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2012) Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS medicine 9:e1001200CrossRefPubMedCentral
6.
Barrett SV, Paul J, Hay A, Vasey PA, Kaye SB, Glasspool RM, Scottish Gynaecological Cancer Trials Group (2008) Does body mass index affect progression-free or overall survival in patients with ovarian cancer? Results from SCOTROC I trial. Ann Oncol 19:898–902CrossRefPubMed
7.
Hess LM, Barakat R, Tian C, Ozols RF, Alberts DS (2007) Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a gynecologic oncology group study. Gynecol Oncol 107:260–265CrossRefPubMedPubMedCentral
8.
Ataseven B, Harter P, Grimm C, Heitz F, Heikaus S, Traut A, Kahl A, Kurzeder C, Prader S, du Bois A (2016) The revised 2014 FIGO staging system for epithelial ovarian cancer: is a subclassification into FIGO stage IVA and IVB justified? Gynecol Oncol. doi:10.​1016/​j.​ygyno.​2016.​05.​021
9.
WHO (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization
10.
Protani MM, Nagle CM, Webb PM (2012) Obesity and ovarian cancer survival: a systematic review and meta-analysis. Cancer Prev Res 5:901–910CrossRef
11.
Zorlini R, Akemi Abe Cairo A, Salete Costa Gurgel M (2008) Nutritional status of patients with gynecologic and breast cancer. Nutr Hosp 23(6):577–583PubMed
12.
Laky B, Janda M, Cleghorn G, Obermair (2008) A comparison of different nutritional assessments and body-composition measurements in detecting malnutrition among gynecologic cancer patients. Am J Clin Nutr 87(6):1678–1685PubMed
13.
Davies M (2005) Nutritional screening and assessment in cancer-associated malnutrition. Eur J Oncol Nurs Suppl 2:S64–S73CrossRef
14.
Malihi Z, Kandiah M, Chan YM, Esfandbod M, Vakili M, Hosseinzadeh M, Zarif Yeganeh M (2015) The effect of dietary intake changes on nutritional status in acute leukaemia patients after first induction chemotherapy. Eur J Cancer Care 24(4):542–552CrossRef
15.
Gil KM, Frasure HE, Hopkins MP, Jenison EL, von Gruenigen VE (2006) Body weight and composition changes in ovarian cancer patients during adjuvant chemotherapy. Gynecol Oncol 103:247–252CrossRefPubMed
16.
Hutton JL, Baracos VE, Wismer WV (2007) Chemosensory dysfunction is a primary factor in the evolution of declining nutritional status and quality of life in patients with advanced cancer. J Pain Symptom Manag 33(2):156–165CrossRef
17.
Enig B, Petersen HN, Smith DF, Larsen B (1987) Food preferences, nutrient intake and nutritional status in cancer patients. Acta Oncol 26(4):301–315CrossRefPubMed
18.
Dell Antone P (2012) Energy metabolism in cancer cells: how to explain the Warburg and Crabtree effects? Med Hypotheses 79(3):388–392CrossRef
19.
Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME (2004) Cancer: disease and nutrition are key determinants of patients’ quality of life. Support Care Cancer 12(4):246–252CrossRefPubMed
20.
Ansell SM, Rapoport BL, Falkson G, Raats JI, Moeken CM (1993) Survival determinants in patients with advanced ovarian cancer. Gynecol Oncol 50:215–220CrossRefPubMed
21.
Kim SI, Kim HS, Kim TH, Suh DH, Kim K, No JH, Chung HH, Kim YB, Song YS (2014) Impact of underweight after treatment on prognosis of advanced-stage ovarian cancer. J Immunol Res 349546
22.
Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T (2016) Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle. doi:10.​1002/​jcsm.​12107 PubMedPubMedCentral
23.
Mardas M, Jamka M, Mądry R, Walkowiak J, Krótkopad M, Stelmach-Mardas M (2015) Dietary habits changes and quality of life in patients undergoing chemotherapy for epithelial ovarian cancer. Support Care Cancer 23:1015–1023CrossRefPubMed
24.
Salminen EK, Lagström HK, Heikkilä S, Salminen S (2000) Does breast cancer change patients’ dietary habits? Eur J Clin Nutr 54:844–848CrossRefPubMed
25.
Van Loon K, Wigler D, Niedzwiecki D, Venook AP, Fuchs C, Blanke C, Saltz L, Goldberg RM, Meyerhardt JA (2013) Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. Clin Colorectal Cancer 12:95–102CrossRefPubMedPubMedCentral
26.
Stephenson LE, Bebb DG, Reimer RA, Culos-Reed SN (2009) Physical activity and diet behaviour in colorectal cancer patients receiving chemotherapy: associations with quality of life. BMC Gastroenterol 9:60–69CrossRefPubMedPubMedCentral
27.
Zhou Y, Chlebowski R, LaMonte MJ, Bea JW, Qi L, Wallace R, Lavasani S, Walsh BW, Anderson G, Vitolins M, Sarto G, Irwin ML (2014) Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women’s Health Initiative. Gynecol Oncol 133:4–10CrossRefPubMedPubMedCentral
28.
Backes FJ, Nagel CI, Bussewitz E, Donner J, Hade E, Salani R (2011) The impact of body weight on ovarian cancer outcomes. Int J Gynecol Cancer 21:1601–1605CrossRefPubMedPubMedCentral
29.
Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME (2005) Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 23(7):1431–1438CrossRefPubMed
30.
Ravasco P, Monteiro Grillo I, Camilo M (2007) Cancer wasting and quality of life react to early individualized nutritional counseling. Clin Nutr 26(1):7–15CrossRefPubMed
31.
Isenring EA, Capra S, Bauer JD (2004) Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer 91(3):447–452CrossRefPubMedPubMedCentral
32.
De Waele E, Mattens S, Honoré PM, Spapen H, De Grève J, Pen JJ (2015) Nutrition therapy in cachectic cancer patients. The Tight Caloric Control (TiCaCo) pilot trial. Appetite 91:298–301CrossRefPubMed
Metadata
Title
Body weight changes in patients undergoing chemotherapy for ovarian cancer influence progression-free and overall survival
Authors
Marcin Mardas
Marta Stelmach-Mardas
Radosław Madry
Publication date
01-03-2017
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 3/2017
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3462-1

Other articles of this Issue 3/2017

Supportive Care in Cancer 3/2017 Go to the issue

Original Article

Short- and long-term use of medication for psychological distress after the diagnosis of cancer

Original Article

Effects of a multimodal rehabilitation programme on inflammation and oxidative stress in oesophageal cancer survivors: the ReStOre feasibility study

Original Article

Return to work among breast cancer survivors: A literature review

Original Article

Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience

Original Article

A nurse-led sexual rehabilitation intervention after radiotherapy for gynecological cancer

Original Article

Participation in treatment decision-making among Chinese-Australian women with breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits